United States · Information technology & services startup

Nurep

Nurep is a Palo Alto-based company founded around 2012-2013 that specializes in telemedicine and telesupport solutions for medical device companies and healthcare professionals.

Funding reportedLast round: Seed

Information technology & servicesPalo Alto, United States

About Nurep

Nurep is a Palo Alto-based company founded around 2012-2013 that specializes in telemedicine and telesupport solutions for medical device companies and healthcare professionals.

The company offers a secure, mobile platform that enables surgeons and care teams to connect live with medical device representatives via video during procedures. This iPad-based system is designed to be HIPAA-compliant, ensuring patient privacy and security. Nurep's services include on-demand remote medical device support, surgical proctoring, and intraoperative assistance. The platform features capabilities such as algorithm-based representative selection, 24/7 support plans, and future enhancements like real-time annotation, session recording, and searchable archives. Its primary users include medical device companies, hospital surgical teams, and physicians who require device support during surgical procedures.

What company datasets say Nurep raised

Funding, as reported

Reported in all$1.7Min dollars
Rounds3
Last roundSeed
Last round size$1.7M
Last round dateJan 2015
Investors listed5

The company, in detail

What they build

Known for

health carecustomer engagementinformation technology & servicestelemedicinehospital & health caremedicalhealthmedical devicesit services & it consultinginternetmobile communicationswellness & fitnessmobile healthhospital supply chainoperating roomhealth care information technology

Built with from their website

Remote

Sector
Information technology & services
Region
California
Full record
Every detail in the company directory

Information technology & services in United States

Startups like it

Is this your company?

Add your raise, your deck and your story, and put Nurep in front of investors. Or tell us what we have wrong.